Corporate ActionMay 5, 2026, 08:48 AM
Clene Prices $7M Registered Direct Offering of 1M Shares
AI Summary
Clene Inc. announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor. The offering is expected to generate approximately $7 million in gross proceeds. Clene plans to use the net proceeds, along with existing cash, for general corporate purposes, including the preparation and filing of the New Drug Application (NDA) for CNM-Au8®, funding ongoing clinical trials, manufacturing expansion, potential commercialization efforts, and additional early-stage research and development activities. The offering is anticipated to close around May 6, 2026.
Key Highlights
- Clene priced a registered direct offering of 1,000,000 shares of common stock.
- Shares were priced at $7.00 per share.
- Gross proceeds from the offering are expected to be approximately $7 million.
- Proceeds will fund NDA preparation for CNM-Au8®, ongoing clinical trials, manufacturing expansion, and R&D.
- The offering is expected to close on or about May 6, 2026.
Price Impact
More from CLNN